iOMEDICO

iOMEDICO

Freiburg, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

iOMEDICO is a specialized, oncology-focused CRO and research institute that bridges clinical practice with advanced research. It operates a dual model, providing full-service clinical trial management while also developing proprietary digital health platforms, including electronic data capture (EDC) systems and AI-powered tools for clinical research and real-world data analysis. The company's unique position is strengthened by its deep investigator network, focus on real-world evidence, and government-funded AI projects, positioning it at the intersection of clinical research and digital innovation in oncology.

OncologyHematology

Technology Platform

Proprietary Electronic Data Capture (EDC) systems, study portals, and AI-powered platforms for clinical trial management (eTMF) and pattern recognition in oncology registry data (NIO project). Focus on digitizing trials and analyzing real-world evidence.

Funding History

2
Total raised:$40M
Series B$25M
Series A$15M

Opportunities

Growing demand for real-world evidence in oncology and AI-driven clinical research tools presents a major opportunity to productize its data assets and technology.
Its specialized focus and deep investigator network provide a defensible niche against larger, generalist CROs.

Risk Factors

Faces intense competition from large global CROs and niche players.
Success is heavily dependent on its investigator network and the uncertain outcome of its AI development projects.
Concentration in the German oncology market adds geographic and therapeutic focus risk.

Competitive Landscape

Competes with large, global full-service CROs (e.g., IQVIA, PPD, ICON) and specialized oncology CROs. Also faces emerging competition from tech companies and RWE analytics firms. Its differentiation lies in its deep oncology specialization, integrated digital platform, and unique real-world data access via its community-based network.